Down syndrome is caused by the presence of an extra copy of chromosome 21, leading to intellectual disability, characteristic physical features, and increased risk of heart defects, Alzheimer's disease, leukemia, and other conditions. It is the most common chromosomal condition, affecting about 1 in 700 births, and life expectancy has improved dramatically with modern medical care.
What's actually going on in research
Research is increasingly focused on cognitive enhancement and the prevention of early-onset Alzheimer's disease, which affects nearly all individuals with Down syndrome by their 60s due to overexpression of the amyloid precursor protein gene on chromosome 21. Trials are testing DYRK1A kinase inhibitors, GABA modulators, and antioxidants to improve cognition, as well as anti-amyloid immunotherapies to delay Alzheimer's-related decline. Adaptive clinical trial designs developed for the general Alzheimer's field are being applied specifically to this population.
Cognitive enhancement drugs
DYRK1A kinase inhibitors and GABA-A alpha 5 modulators are in trials aimed at improving learning, memory, and adaptive function by targeting molecular pathways overactive due to trisomy 21.
Alzheimer's prevention
Because virtually all adults with Down syndrome develop Alzheimer's-related brain changes, anti-amyloid monoclonal antibodies and other disease-modifying therapies are being tested in this population before or at the earliest signs of cognitive decline.
Heart defect outcomes
Surgical and catheter-based strategies for the congenital heart defects present in about half of Down syndrome births are being refined to improve long-term cardiac outcomes and quality of life.
What to know before you search
Eligibility depends on age, cognitive baseline, presence of Alzheimer's symptoms, and for cardiac trials, specific heart defect anatomy.
What types of trials are currently open
- Cognitive therapy trials — Testing drugs targeting DYRK1A, GABA, and other pathways to improve learning and memory.
- Alzheimer's prevention trials — Evaluating anti-amyloid and neuroprotective therapies to delay dementia onset in adults with Down syndrome.
- Heart defect trials — Studying surgical and catheter-based approaches for congenital heart disease in Down syndrome.
- Leukemia trials — Evaluating treatment for Down syndrome-associated acute leukemia, which has distinct biology and treatment sensitivities.
- Behavioral and developmental trials — Testing behavioral, speech, and educational interventions to maximize adaptive function.
Recently added Down Syndrome trials
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Vascular Function in Adults With Down Syndrome
Adults with Down syndrome (Ds) are often thought to have a lower risk of heart and blood vessel disease because they tend to have lower blood pressure and fewer heart attacks than people without Ds. However, recent research suggests that heart and blood vessel diseases, including stroke, are becoming a more common cause of death in adults with Ds as life expectancy increases. Despite these findings, studies examining heart and blood vessel health in adults with Ds have produced mixed results, making it difficult to determine their true risk and whether preventive strategies are needed. This study will investigate the health of blood vessels in adults with Ds and compare the results with those of adults without Ds. Healthy blood vessels are important because they help deliver blood and oxygen throughout the body. Changes in blood vessel function and stiffness can occur with aging and may increase the risk of heart disease, stroke, kidney disease, and memory problems. The study aims to determine whether adults with Ds experience changes in blood vessel health that may place them at increased cardiovascular risk. Specifically, the study will: (1) Examine how well blood vessels function in adults with Ds; (2) Measure the stiffness of arteries in adults with Ds; (3) Compare two methods used to assess blood vessel function to determine whether a simpler exercise-based test provides results similar to a commonly used standard test. The findings may improve understanding of cardiovascular risk in adults with Ds and help guide future strategies to promote healthy aging in this population.
Find Down Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.